% 0期刊文章%一个阿里Gafson查理•麦肯尼% %一个保罗·马修斯康斯坦丁萨瓦% % T延长脂质生物标志物多发性硬化症患者的疾病进展(P2.345) % D J神经病学2017% % P P2.345 X % V % 88% N 16补充目的:进一步描述脂质生物标志物在多发性硬化(MS)患者的代谢组学概要文件。首页背景:临床分期之间的关联和循环lipoprotein-bound胆固醇女士已报告(狄更斯et al . 2014年)。最近的二期临床试验(Chataway et al . 2014年)显示辛伐他汀治疗的功效次要进步表明脂质女士失调可能导致的残疾。设计/方法:等离子体样本来自27个患者复发缓和女士(12米,15 f,平均年龄为41.7±12.5,平均1.5 eds(范围1.0 - -7.0)),治疗至少30天免费,收集和9年龄性别匹配的健康对照组。eds分数评估在采血时间。血浆样品分析by1H-NMR光谱学并验证超速离心法(Beatriz et al .,在出版社)。方差分析(Holm-Bonferroni纠正的方法)进行患者和健康对照组之间比较脂蛋白浓度。皮尔森相关当时执行识别脂质子组和MS患者特征之间的相关性(eds、年龄和性别)。创建一个预测模型使用“test-and-train”例程(75%的训练,25%的测试)来预测组成员通过贝叶斯广义线性模型(GLM)。结果:17脂质子组升高的病人群体相对于控件(方差分析,p < 0.05)。其中,7被排除在外,因为他们的协会可以解释为年龄或性别。剩下的都在统计上显著的脂质差异VLDL和HDL子类(p < 0.05)。 Three sub fractions were positively correlated with EDSS score: VLDL-2-free cholesterol (r=0.466, p=0.02), VLDL-1 cholesterol (r=0.412, p=0.03) and total plasma triglycerides (r=0.420, p=0.03). A General Linear Model based on these could discriminate samples belonging to the patient and control groups with high specificity (1.0) and sensitivity (0.75).Conclusions: We identified associations between novel cholesterol subsets and plasma triglycerides and EDSS in MS patients that are independent of age and sex. These could discriminate disease ‘state’ with high specificity and sensitivity.Disclosure: Dr. Mckechnie has nothing to disclose. Dr. Gafson has nothing to disclose. Dr. Savva has nothing to disclose. Dr. Matthews has received personal compensation for activities with Biogen, Novartis, Ixico, transparency Life Sciences, and Adelphi Communications. Dr. Matthews has received research support from GlaxoSmithKline and Biogen. %U

map